BNGO Bionano Genomics Inc

BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. BioNano Genomics, Inc. also provides Bionano prep kits and labeling kits that provide the critical reagents and protocols needed to extract and label high molecular weight, or HMW, DNA for use with the Saphyr system; and data solutions that includes a suite of hardware and software for experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. The company was formerly known as BioNanomatrix, Inc. and changed its name to BioNano Genomics, Inc. in October 2011. The company was founded in 2003 and is headquartered in San Diego, California.

$7.63  -0.24 (-2.99%)
As of 06/18/2021 15:59:51 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  USA
Country of incorporation:  USA
IPO date:  09/21/2018
Outstanding shares:  278,849,616
Average volume:  22,110,469
Market cap:   $2,191,757,982
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    09075F107
ISIN:        US09075F1075
Sedol:      BFY8K60
Valuation   (See tab for details)
PE ratio:   -52.41
PB ratio:   5.86
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy